- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05046899
Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.
A Prospective, Randomized, Intra-patient Investigation to Assess the Clinical Performance and Safety of BIOpH+ Psoriasis Medical Bath for 8 Weeks of Treatment in Subjects With Mild to Moderate Plaque Psoriasis of Affected Body Area.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Örebro, Sweden, 70362
- Avdelningen för klinisk prövning
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntary agreed to participation and has duly signed Informed Consent Form
- Males and females ≥ 18 years of age
- In the Investigator's opinion, the patient is not likely to become pregnant during study participation (e.g. in a same-sex relationship, not sexually active, sterile, not of child-bearing age, uses contraception, etc.)
- Subject diagnosed with stable mild-moderate plaque psoriasis, defined by PASI ≤ 9
- Intra-individual difference between left and right hemi-body PASI scores not > 1.0
- Patients with symmetrical psoriasis
Exclusion Criteria:
- Presence of other forms of psoriasis other than psoriasis vulgaris (palmoplantar psoriasis, inverse psoriasis, other forms of hyperkeratosis)
- Use of systemic/biological treatment for psoriasis
- Known hypersensitivity or allergy to study products
- Any serious medical condition that could interfere with the evaluation of study results
- Poor compliance in other investigational study, as assessed by investigator
- Pregnant, breastfeeding, or planning to become pregnant during study
- Patients with alcohol -or drug abuse
- Any other conditions as judged by the investigator may make the follow-up or investigation inappropriate
- Anyone unsuitable to participate as subject according to the Declaration of Helsinki
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIOpH+ Psoriasis Medical Bath
BIOpH+ Psoriasis Medical Bath is bath.
Each bath will take 20 minutes and number of bath during the entire study period is approximately 35 baths.
|
20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
|
Active Comparator: Comparative device
Comparative device is Cetaphil Moisturizing Lotion.
The lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
|
Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Psoriasis Area and Severity Index (PASI) score from Baseline compared to week 8.
Time Frame: Baseline and week 8.
|
The PASI score is a validated, investigator instrument assessing the severity of psoriasis.
The severity is combined with the percentage of affected area.
|
Baseline and week 8.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dermatology Life Quality Index (DLQI)
Time Frame: Baseline and week 8.
|
A quality of life instrument and will evaluate how much the skin problems affects the study subject's daily life.
It is a 10-question questionnaire.
Each question contains four response categories: 0=not at all, 1=a little, 2=a lot, and 3=very much.
A higher score means worse outcome.
|
Baseline and week 8.
|
Psoriasis Area Severity Index (PASI)
Time Frame: Week 2 and week 4
|
It combines the severity (erythema, induration and desquamation) and percentage of affected area. A high score means worse outcome. The body is divided into 4 sections:
For each section, the percent of area of skin involved is estimated and graded: 0. 0% of involved area
The sum of all 3 severity parameters is calculated for each body section, multiplied by the area score for that area, and multiplied for the weight of the body section, for a maximum score of 72. |
Week 2 and week 4
|
Physician Global Assessment (PGA)
Time Frame: Baseline, week 2, 4, and 8
|
The Physician Global Assessment, is a 5-point scoring system that will be used to assess the overall disease severity.
This treatment response on each visit will be scored: 0 =cleared, 1=almost clear, 2=mild 3=moderate, and 4=severe.
A higher scores mean worse outcome.
|
Baseline, week 2, 4, and 8
|
Tolerability assessment
Time Frame: Week 2, 4 and week 8.
|
Tolerability assessment completed by the study subject about local tolerance regarding experience of pruritus and burning/stinging measured on a 5-point scale, or by questions to be answered with yes or no.
|
Week 2, 4 and week 8.
|
Usability /satisfaction assessments
Time Frame: Week 8
|
A questionnaire to be answered by study subject about investigational device usability and satisfaction measured on a 5-point scale, or by questions to be answered with yes or no.
|
Week 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martin Lundvall, MD, Research Unit, University Hospital Örebro, Sweden
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BioC002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plaque Psoriasis
-
UCB Biopharma SRLRecruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Biocon Biologics Inc.MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. LtdCompletedHulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and ImmunogenicityModerate Chronic Plaque Psoriasis | Severe Chronic Plaque PsoriasisBulgaria, Czechia, Estonia, Poland
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisChina
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
Clinical Trials on BIOpH+ Psoriasis Medical Bath
-
Medasense Biometrics LtdCompleted
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed